Ionis Pharmaceuticals, Inc. Repayments of Convertible Debt
Ionis Pharmaceuticals, Inc. (IONS) reported Repayments of Convertible Debt of $432.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2024-12-31 was $44.50M.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2023-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for the quarter ending 2023-09-30 was $67.78M.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2024 was $44.50M, a 90.88% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2023 was $487.94M.
- Ionis Pharmaceuticals, Inc. repayments of convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month | Repayments of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $432.51M 10-Q · filed 2026-07-29 | ||||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-07-29 | ||||
| 2024-12-31 | $44.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $44.50M derived: sum of 2 quarters · filed 2026-02-26 | $44.50M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $67.78M derived: sum of 2 quarters · filed 2026-02-26 | $487.94M 10-K · filed 2026-02-26 | $0.00 10-K · filed 2024-02-21 | |
| 2023-09-30 | $67.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $487.94M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $420.16M 10-Q · filed 2024-08-01 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | ||||
| 2021-12-31 | -$195.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$195.00M derived: sum of 2 quarters · filed 2024-02-21 | $61.97M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $256.96M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $256.96M 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |